Results 41 to 50 of about 7,444 (141)

High-dose rifaximin treatment alleviates global symptoms of irritable bowel syndrome

Clinical and Experimental Gastroenterology, 2011
John JolleyDepartment of Medicine, University of California, San Francisco, CA, USABackground: To evaluate the efficacy of rifaximin for reduction of gastrointestinal symptoms in patients with irritable bowel syndrome (IBS).Methods: Medical records were ...
Jolley J
doaj  

Five‐Year CT‐Based Skeletal Muscle Decline Curves in Cirrhosis According to Liver Functional Reserve and Routinely Available Clinical Factors

JGH Open, Volume 10, Issue 10, October 2026.
ABSTRACT Background Sarcopenia is common in cirrhosis and is associated with poor outcomes. We aimed to identify factors associated with longitudinal skeletal muscle loss and to explore estimation of future L3 skeletal muscle index (L3‐SMI) using routinely available clinical variables. Methods This retrospective longitudinal study included 175 patients
Suguru Miida, Hiroteru Kamimura, Hitoshi Yoshiji, Masahito Shimizu, Takumi Kawaguchi, Tetsuya Tsuji, Saori Endo, Hiroki Natsui, Hiroki Maruyama, Hiroyuki Abe, Tadashi Namisaki, Takao Miwa, Dan Nakano, Michiyuki Kawakami, Shuji Terai   +14 more
wiley   +1 more source

Rifaximin and Crohn’s disease

World Journal of Gastroenterology, 2013
In a recent article, Longman and Swaminath analyzed our paper on the use of rifaximin in patients with moderately active Crohn's disease (CD). Here we report some considerations concerning their article. The exploratory post-hoc subgroup analysis showed that early-stage disease and, differently from that written by Longman and Swaminath, also colonic ...
Cosimo, Prantera, Maria Lia, Scribano
openaire   +2 more sources

Effect of Rifaximin on Hepatic Fibrosis in Bile Duct-ligated Rat Model

The Korean Journal of Gastroenterology, 2017
Background/Aims: The translocation of bacteria and their lipopolysaccharides from the gut can promote fibrosis in cirrhotic patients. The aim of this study was to investigate the effects of rifaximin on hepatic fibrosis in a bile duct-ligated rat model ...
Seung Kak Shin, Oh Sang Kwon, Jong Joon Lee, Yeon Ho Park, Cheol Soo Choi, Sung Hwan Jeong, Duck Joo Choi, Yun Soo Kim, Ju Hyun Kim   +8 more
doaj   +1 more source

Mechanism of action and therapeutic benefit of rifaximin in patients with irritable bowel syndrome: a narrative review

Therapeutic Advances in Gastroenterology, 2020
Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder with a multifactorial pathophysiology. The gut microbiota differs between patients with IBS and healthy individuals.
William D. Chey, Eric D. Shah, Herbert L. DuPont   +2 more
doaj   +1 more source

A Multicenter, Prospective Real‐World Study of Simethicone–Activated Charcoal in Patients With Persistent Dyspeptic Symptoms Despite Acid Suppression (SIMAC Study)

JGH Open, Volume 10, Issue 10, October 2026.
ABSTRACT Background Persistent gas‐predominant dyspeptic symptoms affect many patients despite adequate proton pump inhibitor (PPI) therapy, reflecting mechanisms beyond acid secretion. We evaluated the real‐world effectiveness and safety of simethicone (80 mg) plus activated charcoal (250 mg) in adults with persistent symptoms despite prior PPI ...
Ashish Kumar, D. V. Sreenivas, Sambit Kumar Behera, Guduru Raghavendra Srinivas Rao, G. S. Sameer Kumar, Jaya Ghosh Chatterjee, Nalini Kant Choudhary, Ravi Shankar Bagepally, Shekhar Puri, S. M. A. Rizvi, Rahul Pathak, Shruti Pal   +11 more
wiley   +1 more source

Review article: Immunosuppression in Decompensated Autoimmune Hepatitis Cirrhosis ‐ To Suppress or Not to Suppress?

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 7, Page 897-918, October 2026.
Individualized assessment identifies patients with decompensated autoimmune hepatitis cirrhosis who are likely to benefit from a time‐limited trial of immunosuppression versus those requiring immediate liver transplant evaluation. Early objective response monitoring (bilirubin, MELD‐Na and AST/ALT) guides continuation of immunosuppression, promotes ...
Pedro Robson Costa Passos, Valbert Oliveira Costa Filho, Guilherme Grossi Lopes Cançado   +2 more
wiley   +1 more source

A 7‐mm Covered TIPS Reduces Hepatic Encephalopathy Without Increasing Rebleeding in Cirrhotic Patients With Small Liver: A Randomized Study

Liver International, Volume 46, Issue 10, October 2026.
ABSTRACT Background/Aims International guidelines recommend initiating transjugular intrahepatic portosystemic shunt (TIPS) placement with an 8‐mm stent. However, there is an evident lack of randomized controlled trials evaluating TIPS diameters < 8 mm in cirrhotic patients with a relatively small liver. The aim of this study was to determine whether 7 
Fuquan Liu, Kan Zhang, Yu Zhang, Quanwei He, Mingming Meng, Xuemei Ma, Bing Zhu, Yifan Wu, Linjing An, Yifan Lv, Fuhuang Lin, Ke Zhang, Bowen Liu, Xiujuan Chang, Huiguo Ding, Jiangtao Liu, Yan Chen, Yongping Yang   +17 more
wiley   +1 more source

Rifaximin Treatment of Collagenous Colitis: A Randomised, Double-Blind, Placebo-Controlled Trial

Inflammatory Intestinal Diseases
Introduction: Collagenous colitis (CC) is a disabling disease primarily affecting elderly women. Sparse, well-documented treatment modalities exist, except for budesonide. Long-term and repetitive treatment with budesonide is often necessary.
Sabine Becker, Louise B. Grode, Ole K. Bonderup   +2 more
doaj   +1 more source

Microalgae Hybrid Biosystem for Enhanced Oral Delivery of Rifaximin in Hepatic Encephalopathy Treatment

Advanced Science, Volume 13, Issue 54, 28 September 2026.
The microalgae‐nanoparticle hybrid system with antibacterial activity can improve the oral delivery and therapeutic efficiency for hepatic encephalopathy treatment. Oral administration of the system can reduced systemic ammonia levels, enhanced intestinal barrier function, attenuated systemic and neuroinflammation, ameliorated cognitive impairments ...
Kaiyue Wang, Xueting Huang, Lingxiao Yang, Jin Liu, Lei Lei, Shaomin Zou, Kai Wang, Min Zhou, Zhe Tang   +8 more
wiley   +1 more source